Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)
Shots:-
- Novartis presented data at ASN Kidney Week’24 from P-III (APPEAR-C3G) study of Fabhalta (factor B inhibitor) + supportive care to treat adult individuals with C3 glomerulopathy (C3G)
- P-III (APPEAR-C3G) assessed the safety and efficacy of oral Fabhalta (200mg, BID) vs PBO in C3G adult individuals for 6mons. followed by an additional 6mons. of Fabhalta administration in all incl. PBO receiving individual
- The study demonstrated proteinuria reduction as early as 2wks. and maintained at 12mons. with individuals switched to Fabhalta also showed reduction. Additionally, improvement in eGFR slope with a favorable safety profile was observed. US regulatory submission for Fabhalta was expected by the 2024 end
Ref: Novartis | Image: Novartis
Related News:- Novartis’ Kisqali (Ribociclib) Gains the CHMP’s Positive Opinion as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer (EBC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
